Overview

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

Status:
Recruiting
Trial end date:
2022-10-16
Target enrollment:
Participant gender:
Summary
Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440.
Phase:
Phase 1
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra
Collaborator:
DNAtrix, Inc.